Page last updated: 2024-12-09

Methylenedioxycinnamic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID643181
CHEMBL ID1173153
CHEBI ID81482
SCHEMBL ID79427

Synonyms (70)

Synonym
BB 0221182
acetic acid, piperonylidene-
3-(3,4-methylenedioxyphenyl)propenoic acid
2373-80-0
nsc-5953
3,4-methylenedioxybenzene-3-acrylic acid
3,4-(methylenedioxy)cinnamic acid
3,4-methylenedioxycinnamic acid
inchi=1/c10h8o4/c11-10(12)4-2-7-1-3-8-9(5-7)14-6-13-8/h1-5h,6h2,(h,11,12)/b4-2
3-(1,3-benzodioxol-5-yl)acrylic acid
2-propenoic acid, 3-(1,3-benzodioxol-5-yl)-
CS-002/03843060
3,4-(methylenedioxy)cinnamic acid, predominantly trans, 99%
(2e)-3-(1,3-benzodioxol-5-yl)prop-2-enoic acid
STK020097
HMS1397A21
(e)-3-(1,3-benzodioxol-5-yl)prop-2-enoic acid
C18077
methylenedioxycinnamic acid
M0634
3-piperonylacrylic acid
chebi:81482 ,
CHEMBL1173153 ,
3,4-methylenedioxy cinnamic acid
AKOS000120493
A4949
(e)-3-(benzo[d][1,3]dioxol-5-yl)acrylic acid;3,4-(methylenedioxy)cinnamic acid, predominantly trans
NCGC00182231-01
(2e)-3-(1,3-benzodioxol-5-yl)-2-propenoic acid
BBL012089
x8h0wpj08y ,
38489-76-8
2-propenoic acid, 3-(1,3-benzodioxol-5-yl)-, (e)-
unii-x8h0wpj08y
(2e)-3-(2h-1,3-benzodioxol-5-yl)prop-2-enoic acid
3-(3,4-methylenedioxyphenyl) acrylic acid
piperonyl acrylic acid
3-(1,3-benzodioxol-5-yl)-2-propenoic acid
(2e)-3-(1,3-benzodioxol-5-yl)acrylic acid
3-(benzo[d][1,3]dioxol-5-yl)acrylic acid
S11884
3,4-methylenedioxycinnamic acid [who-dd]
3,4-methylenedioxycinnamic acid, (e)-
(e)-3-(benzo[d][1,3]dioxol-5-yl)acrylic acid
SCHEMBL79427
3,4-(methylenedioxy)cinnamic acid, predominantly trans
W-107380
cinnamic acid, 3,4-(methylenedioxy)-
cinnamic acid, 3,4-(methylenebis(oxy))-
3,4-(methylenedioxy)cinnamic acid, pred.trans
F2191-0041
JS-3011
bdbm50486070
(e)-3-benzo[1,3]dioxol-5-yl-acrylic acid
CS-W010709
Q27155410
[(5-bromo-1-pyrazolyl)sulfonyl]dimethylamine
3,4-methylendioxycinnamic acid
DTXSID80901400
3,4-(methylenedioxy)cinnamic acid predominantly trans
3-(1,3-benzodioxol-5-yl)propenoic acid
(e)-3-(1,3-benzodioxol-5-yl)-2-propenoic acid
(2e)-3-(1,3-dioxaindan-5-yl)prop-2-enoic acid
EN300-331721
PD169669
HY-W009993
3-(1,3-dioxaindan-5-yl)prop-2-enoic acid
EN300-16833
(e)-3-(benzo[d][1,3]dioxol-5-yl)acrylicacid
Z56789057

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Intranasal administration of low dosage (<1."( Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
Cheng, TJ; Cheng, YS; Fang, JM; Jan, JT; Liu, KC; Wang, SY; Wong, CH; Yang, ST, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycinnamic acidAny member of the class of cinnamic acids carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
flap endonuclease 1Homo sapiens (human)Potency31.62280.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NeuraminidaseInfluenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)100.00000.00040.13430.9930AID716614
Transitional endoplasmic reticulum ATPaseHomo sapiens (human)IC50 (µMol)30.00000.07002.19396.6100AID1730636; AID1730637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
DNA repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
double-strand break repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-dependent protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
NADH metabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum to Golgi vesicle-mediated transportTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
autophagyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
DNA damage responseTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
proteasomal protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of mitochondrial membrane potentialTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
macroautophagyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein ubiquitinationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
viral genome replicationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
translesion synthesisTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
retrograde protein transport, ER to cytosolTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endosome to lysosome transport via multivesicular body sorting pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cellular response to heatTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
stress granule disassemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
interstrand cross-link repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ERAD pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of apoptotic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
establishment of protein localizationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of protein catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
negative regulation of smoothened signaling pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATP metabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of synapse organizationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum stress-induced pre-emptive quality controlTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
aggresome assemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cellular response to misfolded proteinTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
flavin adenine dinucleotide catabolic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
autophagosome maturationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein-DNA covalent cross-linking repairTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
negative regulation of protein localization to chromatinTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of protein K63-linked deubiquitinationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of Lys63-specific deubiquitinase activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of aerobic respirationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cellular response to arsenite ionTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of oxidative phosphorylationTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
regulation of protein localization to chromatinTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
positive regulation of ATP biosynthetic processTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
mitotic spindle disassemblyTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
RNA bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATP bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
lipid bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATP hydrolysis activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein phosphatase bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein domain specific bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
polyubiquitin modification-dependent protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin protein ligase bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
deubiquitinase activator activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
K48-linked polyubiquitin modification-dependent protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
MHC class I protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
identical protein bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ADP bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-like protein ligase bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-modified protein reader activityTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
BAT3 complex bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ubiquitin-specific protease bindingTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
extracellular regionTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
nucleusTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
nucleoplasmTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytoplasmTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulumTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
endoplasmic reticulum membraneTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
lipid dropletTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytosolTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytoplasmic stress granuleTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
VCP-NPL4-UFD1 AAA ATPase complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
secretory granule lumenTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
azurophil granule lumenTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
site of double-strand breakTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
intracellular membrane-bounded organelleTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
perinuclear region of cytoplasmTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
extracellular exosomeTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
glutamatergic synapseTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ficolin-1-rich granule lumenTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
VCP-NSFL1C complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
proteasome complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
protein-containing complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
Derlin-1 retrotranslocation complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
ATPase complexTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
cytosolTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
nucleusTransitional endoplasmic reticulum ATPaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1226087Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion by ELISA2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID1327731Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 2 days by CytoTox-Glo assay2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
AID1730636Inhibition of His6-tagged p97 (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as reduction in ATPase activity measured after 60 mins by biomol green reagent based assay2021European journal of medicinal chemistry, Mar-05, Volume: 213A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
AID1226086Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID716598Cytotoxicity against MDCK cells at 100 uM2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1226089Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion by ELISA2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID750753Inhibition of Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus laevis oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents at 100 uM after 30 secs by voltage clamp technique2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID1226092Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID1226091Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication by real-time fluorescence quantitative PCR analysis2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID1730637Inhibition of p97 in human HeLa cells assessed as reduction in proteasomal turnover of p97-dependent reporter substrate UbG76V-GFP incubated for 120 mins by luciferase reporter gene assay2021European journal of medicinal chemistry, Mar-05, Volume: 213A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
AID1730638Inhibition of proteasomal turnover of p97-independent ODD-luciferase reporter substrate in human HeLa cells incubated for 120 mins by luciferase reporter gene assay2021European journal of medicinal chemistry, Mar-05, Volume: 213A covalent p97/VCP ATPase inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells.
AID716597Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of LPS induced TNFalpha production treated 30 mins prior to LPS challenge measured after 6 hrs by RT-PCR analysis2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID750756Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID716602Antiinflammatory activity in LPS-activated mouse RAW264.7 cells assessed as inhibition of LPS induced IL6 production treated 30 mins prior to LPS challenge measured after 6 hrs by RT-PCR analysis2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1226088Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID1327728Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by p24 ELISA2016Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19
Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
AID716614Inhibition of Influenza A virus A/WSN/1933(H1N1)) neuraminidase in the presence of 2'-(4-methyl-umbelliferyl)-alphaD-N-acetylneuraminic acid substrate after 10 mins by fluorometric assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID594382Displacement of [3H]nicotinic acid from human GPR109a receptor expressed in human HEK293T cells at 10 uM by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A).
AID750752Dissociation constant, pKa of the compound2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID1226090Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion2015European journal of medicinal chemistry, May-05, Volume: 95Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents.
AID716613Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID492140Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay2010Journal of natural products, Jul-23, Volume: 73, Issue:7
An efficient and economical MTT assay for determining the antioxidant activity of plant natural product extracts and pure compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (77.78)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]